GLP-1 Price Tracker: What Changed This Month

Current Brand-Name Self-Pay Pricing

Introductory Offers Still Active

Both manufacturers are running promotional pricing for new self-pay patients:

• Novo Nordisk: New Wegovy and Ozempic patients pay $199/month for the first two fills at the lowest two doses. Available through NovoCare Pharmacy and retail partners. Offer expires June 30, 2026.
• Eli Lilly: Zepbound multi-dose pen pricing on LillyDirect starts at $299 for the lowest dose. Also available through Walmart Pharmacy pickup.
• Novo Nordisk: Wegovy pill 4mg promotional rate of $149/month expires August 31, 2026 — price increases to $199/month after that.

Insurance & Savings Card Pricing

For patients with commercial insurance coverage:

• Wegovy Savings Card: As low as $25/month with eligible commercial insurance (max savings $100/month, valid up to 48 months)
• Zepbound Savings Card: As low as $25/month with eligible commercial insurance
• Without coverage: Some commercial insurance patients without GLP-1 coverage may access Zepbound for reduced rates through the savings program

Government beneficiaries (Medicare, Medicaid, TRICARE, VA) are not eligible for manufacturer savings cards. The Medicare GLP-1 Bridge program ($50/month copay) launching July 2026 is the first dedicated program for this population.

Compounded Market Update

The compounded GLP-1 market continues to contract under FDA enforcement. Key developments this month:

• The FDA sent enforcement actions to 30+ telehealth companies in March 2026 for misleading advertising of compounded GLP-1 products
• Companies cannot claim their compounded products are "generic," "equivalent," or produce "identical outcomes" to FDA-approved drugs
• Compounded semaglutide pricing among still-operating providers ranges from approximately $200–$400/month, though availability is less predictable than six months ago
• Some providers have shifted from compounded semaglutide to compounded tirzepatide, which has faced different (though evolving) legal dynamics

What's Coming Next

April–June 2026

• Novo introductory offer expiration (June 30): New patient $199/month pricing ends. If you're considering Wegovy or Ozempic at self-pay rates, starting before this date locks in the intro pricing for two fills.
• BALANCE Model Medicaid launch (May 2026): Participating states begin offering GLP-1 coverage through the new CMS model. Check whether your state has opted in.
• Medicare GLP-1 Bridge details (Spring 2026): CMS expected to release prior authorization processes and pharmacy participation details for the July 2026 launch.

July–December 2026

• Medicare GLP-1 Bridge launch (July 1): Eligible Medicare Part D beneficiaries can access Wegovy and Zepbound for $50/month. Nationwide. No plan opt-in required.
• Wegovy pill promo expiration (August 31): The 4mg Wegovy pill promotional rate of $149/month increases to $199/month.
• Orforglipron FDA decision (late 2026): Eli Lilly's oral GLP-1 pill — potential approval could add another low-cost option at $149–$399/month.
• CagriSema FDA decision (~October 2026): Novo Nordisk's next-gen combo — if approved, another brand-name option enters the market.

2027

• BALANCE Model Part D launch (January 2027): Medicare Part D plans that opted in begin covering GLP-1s for weight management as part of the standard benefit.
• IRA-negotiated Ozempic pricing (January 2027): Under the Inflation Reduction Act, Medicare's negotiated price for semaglutide products takes effect — estimated at approximately $274/month.
• Generic Saxenda (liraglutide): Potential generic entry could make liraglutide the first generic GLP-1 option.

Price Changelog

This page is updated monthly. Bookmark it and check back for the latest changes. All prices verified directly against manufacturer websites and programs.